{"nctId":"NCT01069289","briefTitle":"Efficacy and Safety Study of Symbicort速 Turbuhaler速 Versus Oxis速 Turbuhaler速 in Chronic Obstructive Pulmonary Disease (COPD) Patients","startDateStruct":{"date":"2010-01"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":1293,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Budesonide/formoterol (Symbicort Turbuhaler)"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Formoterol (Oxis Turbuhaler)"]}],"interventions":[{"name":"Budesonide/formoterol (Symbicort Turbuhaler)","otherNames":["Symbicort Turbuhaler"]},{"name":"Formoterol (Oxis Turbuhaler)","otherNames":["Oxis Turbuhaler"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A current clinical diagnosis of Chronic Obstructive Pulmonary Disease\n* Documented Chronic Obstructive Pulmonary Disease symptoms for more than 2 years\n* A smoking history of at least 10 pack years\n\nExclusion Criteria:\n\n* History and/or current clinical diagnosis of asthma\n* History and/or current clinical diagnosis of atopic diseases such as allergic rhinitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pre-dose Forced Expiratory Volume in One Second (FEV1)","description":"The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.6","spread":null},{"groupId":"OG001","value":"101.5","spread":null}]}]}]},{"type":"SECONDARY","title":"1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1)","description":"The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113.9","spread":null},{"groupId":"OG001","value":"111.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Pre-dose Forced Vital Capacity (FVC)","description":"The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102.2","spread":null},{"groupId":"OG001","value":"100.9","spread":null}]}]}]},{"type":"SECONDARY","title":"1 Hour Post-dose Forced Vital Capacity (FVC)","description":"The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110.1","spread":null},{"groupId":"OG001","value":"108.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Exacerbations","description":"A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"16.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation","description":"A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 12-week randomization treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"151","spread":null}]}]}]},{"type":"SECONDARY","title":"Morning Peak Expiratory Flow(PEF)","description":"The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.29","spread":"36.58"},{"groupId":"OG001","value":"-4.78","spread":"30.61"}]}]}]},{"type":"SECONDARY","title":"Evening Peak Expiratory Flow (PEF)","description":"The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.55","spread":"36.57"},{"groupId":"OG001","value":"-5.13","spread":"31.52"}]}]}]},{"type":"SECONDARY","title":"Total Number of Day With Exacerbation","description":"Total number of days with COPD exacerbation for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"653","spread":null},{"groupId":"OG001","value":"1098","spread":null}]}]}]},{"type":"SECONDARY","title":"Morning Forced Expiratory Volume in One Second (FEV1)","description":"The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0244","spread":"0.2136"},{"groupId":"OG001","value":"-0.0312","spread":"0.1712"}]}]}]},{"type":"SECONDARY","title":"Evening Forced Expiratory Volume in One Second (FEV1)","description":"The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0176","spread":"0.2268"},{"groupId":"OG001","value":"-0.0324","spread":"0.1724"}]}]}]},{"type":"SECONDARY","title":"Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms","description":"Scored 0 to 1 (0 = no awakening and 1 = awakening). The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.67"},{"groupId":"OG001","value":"-0.15","spread":"0.66"}]}]}]},{"type":"SECONDARY","title":"Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms","description":"There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"0.66"},{"groupId":"OG001","value":"-0.23","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms","description":"There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.70"},{"groupId":"OG001","value":"-0.24","spread":"0.68"}]}]}]},{"type":"SECONDARY","title":"Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score","description":"The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"1.62"},{"groupId":"OG001","value":"-0.61","spread":"1.56"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication","description":"The change from Run-in period average to Treatment period average for each treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"1.51"},{"groupId":"OG001","value":"-0.26","spread":"1.49"}]}]}]},{"type":"SECONDARY","title":"St George's Respiratory Questionnaire (SGRQ) Total Score","description":"The change from Run-in period average to Treatment period average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.37","spread":"14.544"},{"groupId":"OG001","value":"-2.90","spread":"13.783"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":43,"n":636},"commonTop":["Nasopharyngitis","Chronic Obstructive Pulmonary Disease"]}}}